

Robert Rigobello, MS¹, Matthew Hoi Kin Chau, PhD^{1,2}, Xiaonan Zhao, PhD^{1,2}, Christine M. Eng, MD^{1,2}

¹ Baylor Genetics Laboratory, Houston, TX, USA.

² Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, USA.

* No additional relevant disclosures

TAKEAWAYS

- Whole genome sequencing (WGS) identifies multi-locus findings in over 5% of patients
- These findings comprise multiple types of variants, some of which next-generation sequencing (NGS) panels or whole exome sequencing (WES) alone would not capture
- WGS offers a comprehensive testing solution that can readily provide a complete diagnosis of a patient's phenotype and enable better clinical understanding of rare disease

BACKGROUND

- Whole genome sequencing (WGS) offers a comprehensive solution for genetic investigation by capturing a wide range of genomic variations in a single test
- Conventional phenotype-driven and stepwise genetic testing can be costly, time-consuming, and may yield inconclusive results
- The genetic investigation paradigm often stops at the point of identifying a single diagnosis, potentially overlooking additional underlying genetic etiologies
- WGS is recommended as a first- or second-tier test by the American College of Medical Genetics and Genomics (ACMG) for patients with multiple congenital anomalies (MCA), developmental delay (DD), and intellectual disability (ID)
- Limited data exist on the frequency of patients receiving multiple genetic diagnoses pertaining to their phenotype

OBJECTIVES

- To understand the frequency, type, associated indication, and other characteristics of multiple genetic diagnoses made by WGS

METHODS

- WGS results from 1,382 consecutive individuals who were referred for investigation of genetic conditions at Baylor Genetics were evaluated
- The molecular findings and characteristics of the variants contributing to multiple diagnoses were examined

RESULTS

- Reportable multi-locus findings were detected in 78 cases (5.6%), including:
 - 26 cases with dual molecular diagnoses (pathogenic or likely pathogenic variants)
 - 1 case with an actionable secondary finding (SF)
 - 1 case with a reportable finding in another locus [2 variants in an autosomal recessive (AR) locus or 1 variant in an autosomal dominant (AD) locus]
 - 1 case with triple molecular diagnoses
 - 37 cases with one diagnosis with reportable finding(s) in another locus
 - 7 cases with one molecular diagnosis and one reportable variant in an AR locus
 - 7 cases with one molecular diagnosis and an actionable SF
- Among the 24 cases with dual diagnoses, the most common clinical indications included:
 - MCA (n=21)
 - DD/ID (n=7)
 - Seizures (n=3)
 - Failure to thrive (n=4)
- Parental samples were available in 13 cases with dual diagnoses which revealed that *de novo* findings accounted for at least one of the diagnostic variants in 11 trios

FIGURE 1




Figure 1: The proportion of WGS and Rapid WGS yielding single and multiple molecular diagnoses. Dx, diagnosis(es). SF, secondary findings based on the ACMG v3.2 gene list. A possible diagnosis is defined by one VUS in an autosomal dominant disease-causing locus or one pathogenic/likely pathogenic variant in addition to a VUS in an autosomal recessive disease-causing locus.

FIGURE 2




Figure 2: A & B. The mode of inheritance of the loci and variant types contributing to multiple molecular diagnoses in 27 cases. AD, autosomal dominant; AR, autosomal recessive; XL, X-linked; MT, mitochondrial; SNV, single nucleotide variant; Indel, small insertions and deletions; CNV, copy-number variant; TNR, triplet repeat expansion.

FIGURE 3




Figure 3: Approximately half of the multiple diagnoses involved a combination of different variant types. WGS or multiple lines of testing would be required to reach these multiple diagnoses.

CONCLUSIONS

- This study demonstrates the utility of WGS to provide reportable multi-locus findings involving multiple types of variants
- WGS can expedite resolution of diagnostic odysseys and aid in optimizing management of critically ill patients with complex phenotypes in the NICU, PICU, and other settings
- Recognition of the clinical effects of multiple variants at more than one locus will also improve understanding of rare disease